In the present work, the anti-inflammatory and antiasthmatic potential of 
biseugenol, isolated as the main component from n-hexane extract from leaves of 
Nectandra leucantha and chemically prepared using oxidative coupling from 
eugenol, was evaluated in an experimental model of mixed-granulocytic asthma. 
Initially, in silico studies of biseugenol showed good predictions for 
drug-likeness, with adherence to Lipinski's rules of five (RO5), good 
Absorption, Distribution, Metabolism and Excretion (ADME) properties and no 
alerts for Pan-Assay Interference Compounds (PAINS), indicating adequate 
adherence to perform in vivo assays. Biseugenol (20 mg·kg-1) was thus 
administered intraperitoneally (four days of treatment) and resulted in a 
significant reduction in both eosinophils and neutrophils of bronchoalveolar 
lavage fluid in ovalbumin-sensitized mice with no statistical difference from 
dexamethasone (5 mg·kg-1). As for lung function parameters, biseugenol (20 
mg·kg-1) significantly reduced airway and tissue damping in comparison to 
ovalbumin group, with similar efficacy to positive control dexamethasone. Airway 
hyperresponsiveness to intravenous methacholine was reduced with biseugenol but 
was inferior to dexamethasone in higher doses. In conclusion, biseugenol 
displayed antiasthmatic effects, as observed through the reduction of 
inflammation and airway hyperresponsiveness, with similar effects to 
dexamethasone, on mixed-granulocytic ovalbumin-sensitized mice.